Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / GCAN - Greater Cannabis rises 25% on submitting phase 2 trial application to treat autism in Israel

GCAN - Greater Cannabis rises 25% on submitting phase 2 trial application to treat autism in Israel

GammaCan International Inc.
  • Greater Cannabis ( OTCQB:GCAN ) said on Friday it had submitted a clinical trial application to the Israel Ministry of Health for approval of a Phase 2 clinical trial for its neuropsychiatric cannabinoid therapy.
  • ( OTCQB:GCAN ) has risen 25% .
  • The Company intends to conduct a Phase 2 clinical trial to study the safety and efficacy of its neuroprotective cannabinoid therapeutic to treat autism related spectrum disorders (ASD) and other neuropsychiatric illnesses.
  • The study will have 100 patients ranging in age from 4-17 years old.
  • The study is expected to begin enrolling patients in the first half of 2023.

For further details see:

Greater Cannabis rises 25% on submitting phase 2 trial application to treat autism in Israel
Stock Information
Company Name: GammaCan International Inc.
Stock Symbol: GCAN
Market: OTC
Website: gcanrx.com
Menu
GCAN GCAN Quote GCAN Short GCAN News GCAN Articles GCAN Message Board
Get GCAN Alerts

News, Short Squeeze, Breakout and More Instantly...